Key Drivers
- High margins
- Robust FCF
- Elevated intangibles
AIAI Summary
Zimmer Biomet's investment thesis has shifted from a steady consumables cash-generator to a higher-risk growth pivot hinging on successful robotics adoption and M&A integration—if management delivers sustained consumable attach-rate growth, quarter-to-quarter margin recovery and stable FCF conversion the stock can re-rate, but failure would trigger margin compression, goodwill impairment risk and multiple contraction.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Robust FCF
- •Elevated intangibles
ZBH delivers strong margins and free cash flow with manageable leverage but modest returns, elevated intangibles and recent quarter margin softness amid a premium valuation.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Oversold RSI
- •Near-term support
Stock is in a short-term downtrend—trading below the last month SMA (~$95) with ~-11% momentum over the last month and an oversold 14-day RSI (~22) setting up for a potential bounce near $87.9–$86.2 but resistance at $95 and $99–$101 must be reclaimed to flip bias.
~-11% decline over the last month with peak near $99–$101 on 2026-02-26
Sentiment & News
Key News Insights:
- •Product/event push
- •Dividend continuity
- •Securities probe
Zimmer Biomet is juggling product/event-driven momentum and a Q1 dividend with mixed analyst sentiment, institutional trimming and a securities-fraud probe, coinciding with modest post-earnings share weakness.
Continued dividends and event visibility support sentiment, but the fraud investigation and institutional selling introduce near-term downside risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings